OncoSec to Host Second Quarter Financial Conference Call on March 16, 2017

SAN DIEGO, March 2, 2017 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that the Company will host its fiscal second quarter 2017 financial results conference call on Thursday, March 16 at 1:15 PM PST/4:15 PM EST.

To access the audio broadcast, please call (877) 731-1960 and enter the conference ID number: 74585937. An archived version of the presentation will be available for 90 days on the "Investors" section of OncoSec's website: http://ir.oncosec.com/events-presentations.

About OncoSec Medical Incorporated

OncoSec is a biotechnology company developing DNA-based intratumoral immunotherapies with an investigational technology, ImmunoPulse^®, for the treatment of cancer.  ImmunoPulse^® is designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as IL-12. In Phase I and II clinical trials, ImmunoPulse^® IL-12 has demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various solid tumors as well as the potential to initiate a systemic immune response. OncoSec's lead program, ImmunoPulse^® IL-12, is currently in clinical development for several indications, including metastatic melanoma, and triple-negative breast cancer. The program's current focus is on the significant unmet medical need in patients with melanoma who are refractory or non-responsive to anti-PD-1/PD-L1 therapies. In addition to ImmunoPulse^® IL-12, the Company is also identifying and developing new immune-targeting agents for use with the ImmunoPulse^® platform. For more information, please visit www.oncosec.com.

CONTACT:
Investor Relations
OncoSec Medical Incorporated
855-662-6732
investors@oncosec.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/oncosec-to-host-second-quarter-financial-conference-call-on-march-16-2017-300416455.html

SOURCE OncoSec Medical Incorporated